1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Adenocarcinoma, Follicular

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Adenocarcinoma, Follicular in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Aghaee, A; Aryana, K; Ataei-Nakhaei, S; Esmatinia, M; Kosari, HM; Mostafavi, SM	1

Other Studies

1 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Adenocarcinoma, Follicular

Article	Year
Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. Archives of endocrinology and metabolism, 2022, Apr-28, Volume: 66, Issue:2 Topics: Adenocarcinoma, Follicular; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Thyroglobulin; Thyroid Neoplasms	2022

Article

Year

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment.

Archives of endocrinology and metabolism, 2022, Apr-28, Volume: 66, Issue:2

Topics: Adenocarcinoma, Follicular; Female; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Iodine Radioisotopes; Middle Aged; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Thyroglobulin; Thyroid Neoplasms

2022